Supplemental Table V. Non-predictive factors of recurrent ischemic stroke

Non-predictive factor	Study	Sample size, n	Variable definition	Factor prevalence	Follow-up duration	uv RR (95% CI)	mv HR (95% CI)
Strong level							
Male sex I^2=0%	Ay 2010	1458	-	54%	90 days	1.1 (0.8-1.3)	
	Bergström 2017	196,765	-	50%	1 year		1.0 (1.0-1.1)
	Buenaflor 2017	1155	-	53%	3 years	1.0 (0.9-1.2)	
	Kim 2014	2378	-	54%	90 days	1.0 (0.8-1.2)	
	Kuwashiro 2012	260	-	58%	12 months	1.2 (0.9-1.6)	OR 1.7 (0.7-4.7)
	Lee 2004	7816	-	51%	4 years		1.2 (1.0-1.3)
	Nam 2017	959	-	62%	31 months	1.0 (0.8-1.2)	
	Soda 2004	745	-	58%	12 months	0.9 (0.7-1.1)	
	Pooled					**1.0 (0.9-1.1)**	
Hypertension I^2=71%	Ay 2010	1458	-	70%	90 days	1.1 (0.9-1.2)	
	Buenaflor 2017	1155	Medication; persistent blood pressure >140/90 mmHg	95%	3 years	1.0 (0.9-1.0)	
	Kim 2014	2378	Medication; repeated ≥140/9mmHg	69%	90 days	1.2 (1.1-1.3)	
	Kuwashiro 2012	260	Medication; SBP≥140;DBP≥90	80%	12 months	1.0 (0.8-1.2)	
	Nam 2017	959	-	66%	31 months	0.9 (0.8-1.2)	
	Soda 2004	736	Medication; >140/90 mmHg; also at two following occasions after index stroke	68%	12 months	1.2 (1.0-1.3)	
	Lai 1994	621	Medical history of hypertension	59%	24 months		2.0 (1.2-3.2)
	Lee 2004	7816	-	62%	4 years		1.1 (0.9-1.2)
	Pooled					**1.1 (1.0-1.2)**	
Dyslipidemia I^2=0%	Buenaflor 2017	1155	Medication; total chol≥240mg/dL;LDL≥160mg/dL	36%	3 years	1.1 (0.9-1.3)	
	Kuwashiro 2012	260	Medication; total chol≥220mg/dL	41%	12 months	0.9 (0.5-1.5)	
	Lee 2004	7816	-	15%	4 years		0.9 (0.7-1.1)
	Nam 2017	959	-	31%	31 months	0.9 (0.6-1.3)	
	Soda 2004	709	Fasting total cholesterol >5.7 mmol/L, fasting triglycerides >1.70 mmol/L, or HDL cholesterol <1.04 mmol/L	39%	12 months	1.4 (0.9-2.3)	
	Pooled					**1.1 (0.9-1.2)**	
DM I^2=39%	Alter 1997	621	History of DM; medication; diet; elevated HbA1c (>6.2%)	32%	24 months	1.1 (0.8-1.6)	
	Ay 2010	1458	-	24%	90 days	0.9 (0.6-1.5)	
	Bergström 2017	196,765	-	21%	1 year		1.2 (1.1-1.3)
	Buenaflor 2017	1155	Medication; fasting glucose≥7mmol/L; symptoms plus random glucose≥11.1mmol/L; HbA1c>6.5%)	25%	3 years	0.8 (0.6-1.0)	
	Kim 2014	2378	Medication; repeated fasting glucose ≥126 mg/dL	23%	90 days	1.0 (0.7-1.4)	
	Kuwashiro 2012	260	Medication; fasting glucose≥126mg/dL; positive 75g oral glucose tolerance test result	34%	12 months	1.5 (0.9-2.3)	
	Nam 2017	959	-	30%	31 months	1.3 (1.0-1.8)	
	Soda 2004	742	Fasting glucose >7.0 mmol/l, positive 75g oral glucose tolerance test result, or HbA1c >6.5%	34%	12 months	1.2 (0.7-1.9)	
	Lee 2004	7816	-	22%	4 years		1.3 (1.1-1.5)
	Pooled					**1.1 (0.9-1.3)**	
AF I^2=18%	Ay 2010	1458	-	30%	90 days	0.8 (0.5-1.3)	
	Buenaflor 2017	1155	By ECG or 24h Holter	17%	3 years	0.9 (0.7-1.3)	
	Lai 1994	621	AF by ECG	16%	24 months		1.8 (1.0-3.1)
	Lee 2004	7816	-	23%	4 years		1.0 (0.9-1.2)
	Kim 2014	2378	-	25%	90 days	0.9 (0.6-1.2)	
	Kuwashiro 2012	260	-	20%	12 months	1.7 (0.9-3.1)	
	Nam 2017	959	-	14%	31 months	1.2 (0.7-2.2)	
	Pooled					**1.0 (0.8-1.2)**	
Anticoagulant I^2=0%	Ay 2010	1458	-	41%	90 days	1.0 (0.8-1.4)	
	Kim 2014	2378	-	37%	90 days	1.1 (0.9-1.4)	
	Kuwashiro 2012	260	-	23%	12 months	1.0 (0.5-2.2)	
	Nam 2017	959	-	13%	31 months	0.9 (0.4-1.8)	
	Soda 2004	745	1 year after index or during recurrent stroke	18%	12 months	1.1 (0.6-2.0)	
	Pooled					**1.1 (0.9-1.3)**	

	Study	N	Definition	%	Follow-up	Effect (CI)
Antiplatelet I²=0%	Ay 2010	1458	-	67%	90 days	1.0 (0.9-1.2)
	Kim 2014	2378	-	70%	90 days	1.0 (0.9-1.1)
	Kuwashiro 2012	260	-	76%	12 months	1.1 (0.9-1.3)
	Nam 2017	959	-	90%	31 months	1.0 (0.9-1.1)
	Pooled					**1.0 (1.0-1.1)**
Statin I²=0%	Ay 2010	1458	-	56%	90 days	0.9 (0.7-1.1)
	Kim 2014	2378	-	66%	90 days	1.0 (0.9-1.2)
	Nam 2017	959	-	71%	31 months	1.0 (0.8-1.2)
	Pooled					**1.0 (0.9-1.1)**
Moderate level						
Alcohol I²=0%	Buenaflor 2017	1155	≥5 drinks on same occasion on each of 5 or more days in the past 30 days	8%	3 years	0.7 (0.4-1.2)
	Kuwashiro 2012	260	Consumption (including occasional drinking)	38%	12 months	1.0 (0.6-1.6)
	Nam 2017	959	-	40%	31 months	1.0 (0.7-1.3)
	Soda 2004	592	Heavy: >43g/day	17%	12 months	0.6 (0.3-1.4)
	Pooled					**0.9 (0.7-1.1)**
Antihypertensive medication I²=0%	Kim 2014	2378	-	28%	90 days	1.0 (0.7-1.3)
	Kuwashiro 2012	260	-	45%	12 months	0.7 (0.4-1.2)
	Nam 2017	959	-	49%	31 months	1.0 (0.7-1.3)
	Pooled					**0.9 (0.8-1.1)**
Limited level						
Other cause vs LAA I²=36%	Ay 2010	1458	CCS	6%	90 days	2.0 (1.0-3.8)
	Kim 2014	2378	CCS	8%	90 days	1.2 (0.8-2.0)
	Kuwashiro 2012	260	TOAST	27%	12 months	0.5 (0.2-1.4)
	Nam 2017	959	TOAST	9%	31 months	1.4 (0.7-2.7)
	Pooled					**1.2 (0.8-1.9)**

uv.: univariable, RR: risk ratio, CI: confidence interval, mv.: multivariable, HR: hazard ratio, OR: odds ratio, mmHg: millimeters of mercury, SBP: systolic blood pressure, DBP: diastolic blood pressure, chol: cholesterol, mg: milligrams, dL: deciliter, LDL: low-density lipoprotein, mmol: millimoles, L:liter, HDL: high-density lipoprotein, DM: diabetes mellitus, g: grams, AF: atrial fibrillation, ECG: electrocardiogram, LAA: large artery atherosclerosis, CCS: Causative Classification System for Ischemic Stroke, TOAST: Trial of ORG 10172 in Acute Stroke Treatment.